Loading…
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-160M | $-177M | $-154M | -176.1% | - | - |
| 2024 | $0M | $-101M | $-112M | $-84M | -96.7% | - | - |
| 2023 | $0M | $-58M | $-64M | $-54M | -45.6% | - | - |
| 2022 | $0M | $-38M | $-40M | $-36M | -30.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 39.39 | 66.23 | 113.27 | 172.19 |
| Operating Income | -39.39 | -66.23 | -113.27 | -172.19 |
| EBITDA | -38.05 | -58.31 | -101.37 | -159.73 |
| EBIT | -38.26 | -58.45 | -101.50 | -159.89 |
| Pretax Income | -40.37 | -63.78 | -111.78 | -177.04 |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income Common Stockholders | -40.37 | -63.78 | -111.78 | -177.04 |
| Total Expenses | 39.39 | 66.23 | 113.27 | 172.19 |
| Interest Expense | 2.11 | 5.33 | 10.28 | 17.15 |
| Interest Income | 1.13 | 7.78 | 11.77 | 12.30 |
| Research And Development | 35.29 | 60.59 | 104.20 | 145 |
| Selling General And Administration | 4.10 | 5.64 | 9.06 | 27.20 |
| Normalized EBITDA | -38.05 | -58.31 | -101.37 | -159.73 |
| Normalized Income | -40.37 | -63.78 | -111.78 | -177.04 |
| Basic EPS | -2.64 | -2.69 | -2.83 | -3.79 |
| Diluted EPS | -2.64 | -2.69 | -2.83 | -3.79 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -40.37 | -63.78 | -111.78 | -177.04 |
| Reconciled Depreciation | 0.21 | 0.14 | 0.13 | 0.17 |
| Net Interest Income | -0.98 | 2.45 | 1.49 | -4.85 |
| Net Income From Continuing And Discontinued Operation | -40.37 | -63.78 | -111.78 | -177.04 |
| Total Operating Income As Reported | -39.39 | -66.23 | -113.27 | -172.19 |
| Diluted Average Shares | 15.42 | 23.68 | 39.45 | 46.76 |
| Basic Average Shares | 15.42 | 23.68 | 39.45 | 46.76 |
| Diluted NI Availto Com Stockholders | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income Including Noncontrolling Interests | -40.37 | -63.78 | -111.78 | -177.04 |
| Net Income Continuous Operations | -40.37 | -63.78 | -111.78 | -177.04 |
| Other Income Expense | 0 | 0 | 0 | 0 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Gain On Sale Of Ppe | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -0.98 | 2.45 | 1.49 | -4.85 |
| Interest Expense Non Operating | 2.11 | 5.33 | 10.28 | 17.15 |
| Interest Income Non Operating | 1.13 | 7.78 | 11.77 | 12.30 |
| General And Administrative Expense | 4.10 | 5.64 | 9.06 | 27.20 |
| Other Gand A | 4.10 | 5.64 | 9.06 | 27.20 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Celcuity Inc.this co. | CELC | $5.8B | - | 57.10 | -176.1% | -32.74 |
| Terns Pharmaceuticals, Inc. | TERN | $6.1B | - | 5.91 | -9.6% | -46.26 |
| Hims & Hers Health, Inc. | HIMS | $6.1B | 51.63 | 11.06 | 23.7% | 37.26 |
| Mirum Pharmaceuticals, Inc. | MIRM | $5.7B | - | 15.53 | -7.4% | 2666.18 |
| CG Oncology, Inc. | CGON | $5.7B | - |
| 6.94 |
| -21.4% |
| -24.99 |
| Rhythm Pharmaceuticals, Inc. | RYTM | $5.6B | - | 39.69 | -72.8% | -28.64 |
| Scholar Rock Holding Corporation | SRRK | $5.5B | - | 20.46 | -154.0% | -13.21 |
| Immunovant, Inc. | IMVT | $5.5B | - | 5.56 | -58.5% | -9.23 |
| Oscar Health, Inc. | OSCR | $5.4B | - | 5.45 | -45.2% | -5.02 |
| Peer Median | - | 51.63 | 9.00 | -33.3% | -11.22 | |